RDHL Redhill Biopharma Ltd.
$0.64▼ -1.29%
Healthcare
Other
After hours
$0.58▼ -10.06%
Sep 11, 7:49 PM ET
Volume 193.1K
Avg Volume (10D) 11.12M
Key Metrics & Fundamentals
Market Cap
$3.92M
P/E Ratio
–
Div Yield
–%
52W Range
0.57 - 2.79
% vs 50 MA
-4.35%
% vs 200 MA
-30.70%
RSI-14
46.6
MACD Histogram
+0.0000
Beta (1Y vs SPY)
0.76
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?
Insider Monkey · Sep 10, 2026 4:06 PM
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
GlobeNewswire · Sep 1, 2026 11:00 AM
Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight
GlobeNewswire · Aug 31, 2026 5:00 PM
Redhill Biopharma Stock Doubles In One Session — Here's Why
Benzinga · Aug 31, 2026 2:06 PM
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
PR Newswire · Aug 31, 2026 11:00 AM
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight
PR Newswire · Jul 30, 2026 2:31 PM
Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
PR Newswire · Jul 28, 2026 11:00 AM
RedHill Biopharma Closes Private Placement
MT Newswires · Jun 22, 2026 8:42 PM
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
PR Newswire · Jun 22, 2026 8:10 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
No Reddit posts found for RDHL.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.